ALFA Finder| Metric | H2 FY26 | H1 FY26 | H2 FY25 |
|---|---|---|---|
| Revenue from operations | 45.9 | 43.7 | 38.8 |
| Other income | 0.1 | 0.1 | 0.1 |
| Total income | 46.0 | 43.8 | 38.9 |
| Profit before exceptional items & tax | 6.7 | 6.4 | 6.5 |
| Profit before tax | 6.7 | 6.4 | 6.5 |
| Net profit | 4.9 | 4.8 | 4.3 |
| Operating margin | 14.6% | 14.6% | 16.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +14.00% |
|---|---|
| Net profit, quarter on quarter | +2.10% |
| Revenue, year on year | +18.30% |
NSE results filing, NSE: ACCPL. Figures extracted from the filing.
Accretion Pharmaceuticals Ltd: key numbers
- Share price
- ₹203.75
- Market cap
- ₹226.5 Cr
- Revenue (annual)
- ₹89.63 Cr
- Net profit (annual)
- ₹9.67 Cr
- P/E (TTM)
- 23.4×Sector 43.8×
- Promoter holding
- 73.52%+0.00% QoQ
- FII holding
- 0.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Accretion Pharmaceuticals Ltd
All →Accretion Pharmaceuticals Investor Presentation: Key Takeaways
H1 FY27 revenue ₹55.04 Cr (+25.83% YoY), PAT ₹8.20 Cr (+72.63%), EBITDA margin 22.48%. Export share rose to 18.15%.
Accretion Pharmaceuticals Results Update
Accretion Pharmaceuticals reported H1 FY27 net revenue up 25.83% to ₹55.04 crore and PAT up 72.63% to ₹8.20 crore via media release. EBITDA margin improved to 22.48%.
Accretion Pharmaceuticals H1 FY27 Results: Net Profit ₹8.2 Cr, Up 70.8% YoY
Accretion Pharmaceuticals reported unaudited standalone half-year results to 30 September 2026, with revenue of Rs 5,504.10 lakh and profit after tax of Rs 820.14 lakh. The results carry a limited review report from VSSB & Associates.
- Key figure
- Net profit ₹8.2 Cr · +70.8% YoY
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited announced the results of its postal ballot, where shareholders approved five special resolutions, including increasing borrowing limits and charging company assets.
Accretion Pharmaceuticals Other Announcement
Accretion Pharmaceuticals Limited submitted the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
Accretion Pharmaceuticals Annual General Meeting
Accretion Pharmaceuticals Limited issued a postal ballot notice to shareholders to seek approval for altering the company's Memorandum of Association (Object Clause).